97933969 - PDPS

Information

• Trademark
• 97933969

• Source

• Serial Number

  97933969

• Registration Number

  7709587

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 40 - Treatment of materials
  • 42 - Scientific and technological services and research and design relating thereto

• Filing Date

  May 12, 2023
  2 years ago

• Registration Date

  March 04, 2025
  12 months ago

• Transaction Date

  March 04, 2025
  12 months ago

• Status Date

  March 04, 2025
  12 months ago

• Published for Opposition Date

  January 14, 2025
  a year ago

• Location Date

  March 03, 2025
  12 months ago

• Status Code

  700

• Current Location

  FILE REPOSITORY (FRANCONIA)

  Employee Name

  DAWE III, BILL

• Attorney Docket Number

  PPDM 13733

  Attorney Name

  Harris A. Wolin

• Owners

  • Peptidream Inc.

Case File Statements

• GS0401: Manufacture of synthetic peptides to the order and specification of others; Peptide synthesis for others, namely, manufacture of synthetic peptides to the order and specification of others; Manufacture of pharmaceuticals and chemicals to the order and specification of others; Manufacture of synthetic proteins to the order and specification of others; Amino acid synthesis for others, namely, manufacture of amino acids to the order and specification of others
• GS0051: Synthesized peptides used in drug discovery of various pharmaceuticals for the treatment of various to different diseases and medical conditions; Chemical preparations used in drug discovery for the treatment of various diseases and medical conditions and for pharmaceutical purposes; Central nervous system drugs, namely, pharmaceutical preparations for the treatment of various diseases and medical conditions affecting the central nervous system; Peripheral nerve drugs, namely, pharmaceutical agents for the treatment of various diseases and medical conditions affecting the peripheral nervous system; Drugs affecting sensory organs, namely, pharmaceutical agents for the treatment of various diseases and medical conditions affecting sensory organs; Antiallergic drugs, namely, pharmaceutical antiallergic preparations and substances; Cardiovascular drugs, namely, cardiovascular pharmaceutical preparations; Drugs affecting respiratory organs, namely, pharmaceutical preparations for treating respiratory diseases; Drugs affecting digestive organs, namely, pharmaceutical preparations for the treatment of various diseases and medical conditions affecting digestive organs; Drugs for outer skin, namely, pharmaceutical preparations for the treatment of various diseases and medical conditions for skin care; Pharmaceutical preparations for the treatment of various diseases and medical conditions of Metabolic disorders; Cellular function activating drugs for the treatment of various diseases and medical conditions for medical purposes; Pharmaceutical preparations for the treatment of various diseases and medical conditions for suppressing tumors; diagnostic preparations for medical purposes; Pharmaceutical preparations using synthesized peptides used in drug discovery and pharmaceuticals for the treatment of various diseases and medical conditions for medical purposes; Synthesized proteins and chemical preparations used in drug discovery and pharmaceuticals for the treatment of various diseases and medical conditions for medical purposes
• GS0011: Chemicals for the manufacture of pharmaceuticals; synthesized peptides for scientific and research use; Reagents for biological and chemical purposes and for research purposes, excluding those for medical or veterinary use; Proteins and synthesized peptides used in the research and the development and manufacture of pharmaceuticals and biologicals; Chemical reagents used for the detection, measurement and identification of genetic materials or compounds, excluding those for medical and veterinary use
• GS0421: Testing, examination, namely, inspection and research services in the field of pharmaceuticals, cosmetics, and foods, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of medical organisms or bacteria, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of chemistry, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of medical care, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of biotechnology, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the identification of hit lead peptides, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the identification of hit-lead compounds, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the analysis and synthesis of peptides, and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the field of the analysis and synthesis of proteins, and the provision of information or advice thereto; The generation of a library of peptides and the provision of information or advice thereto; Testing, examination, namely, inspection and research services in the fields of pharmaceuticals, cosmetics, foods, medical organisms or bacteria, chemistry, medical care, biotechnology, identification of hit lead peptides, analysis and synthesis of peptides, using automated screening machines and the provision of information or advice thereto; Scientific research in the nature of conduction of clinical trials for others; Quality control of peptides used in drug development; Advice on quality control of peptides used in drug development

Case File Event Statements

• 5/16/2023 - 2 years ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 6/12/2023 - 2 years ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 2/6/2024 - 2 years ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 2/7/2024 - 2 years ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 2/7/2024 - 2 years ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 2/7/2024 - 2 years ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 9/18/2024 - a year ago

  10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 5/7/2024 - a year ago

  7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 9/18/2024 - a year ago

  9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 9/24/2024 - a year ago

  12 - NON-FINAL ACTION E-MAILED Type: GNRT

• 9/24/2024 - a year ago

  11 - NON-FINAL ACTION WRITTEN Type: CNRT

• 9/18/2024 - a year ago

  8 - ASSIGNED TO LIE Type: ALIE

• 9/24/2024 - a year ago

  13 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 12/10/2024 - a year ago

  16 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 12/10/2024 - a year ago

  15 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 12/10/2024 - a year ago

  14 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 12/13/2024 - a year ago

  17 - ASSIGNED TO LIE Type: ALIE

• 12/13/2024 - a year ago

  18 - DATA MODIFICATION COMPLETED Type: DMCC

• 12/17/2024 - a year ago

  22 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 12/17/2024 - a year ago

  20 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 12/17/2024 - a year ago

  21 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 12/17/2024 - a year ago

  19 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 12/18/2024 - a year ago

  23 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA

• 1/8/2025 - a year ago

  24 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP

• 1/14/2025 - a year ago

  25 - PUBLISHED FOR OPPOSITION Type: PUBO

• 1/14/2025 - a year ago

  26 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB

• 3/4/2025 - 12 months ago

  27 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC

• 3/4/2025 - 12 months ago

  28 - REGISTERED-PRINCIPAL REGISTER Type: R.PR